Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin Evades U.S. Patent Battle With Warner Chilcott For Oral Contraceptives

This article was originally published in PharmAsia News

Executive Summary

WASHINGTON - Indian generic drug maker Lupin may have cleared a big hurdle in its pursuit to launch generic versions of Warner Chilcott's oral contraceptive drugs Loestrin 24 Fe and Femcon in the United States as the Irish company - specializing in dermatology and women's health products - decided to back out from a patent lawsuit it filed at the U.S. District Court of Maryland
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC070206

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel